Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
5
×
national blog main
national top stories
san diego blog main
san diego top stories
san francisco blog main
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
regeneron pharmaceuticals
alirocumab
amgen
clinical trials
deals
drugs
alder biopharmaceutical
alex azar
allergan
alnylam pharmaceuticals
ambys medicines
american academy of neurology
What
drug
5
×
drugs
5
×
new
fda
long
prices
advance
afternoon
anticipated
approval
aren’t
arguments
awaited
big
bio
biologic
biology
blueprint
cholesterol
class
commercialized
companies
competitors
cost
cut
cytokine
decades
demonstrating
details
developers
diego’s
enhanced
expensive
faces
financial
foe
gene
healthcare
help
hint
Language
unset
Current search:
drug
×
drugs
×
" life sciences "
×
@xconomy.com
5 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
6 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs